(MENAFNEditorial) First bioelectric cancer tumor therapy designed for early detection, personalized real time reading, customized communication jamming, stopping cell division, starving blood supply, changing surface protein expression to trigger immunotherapy, customized real time inflammation management and then regenerating the affected organ after cancer tumor is eradicated
Playa Vista, CA and Salt Lake City, Utah / PRBUZZ / October 19th, 2017 / CancerCell a startup incubating within the Leonhardt's Launchpads innovation accelerator labs in California and Utah has announced it has filed new provisional patent application claims for bioelectric cancer tumor treatment. These claims include:
1. Bioelectric signals to provide early detection of cancer tumors.
2. Bioelectric signal to read real time the communication signals and protein expressions of a cancer tumor.
3. Delivery of customized bioelectric signals real time to jam the ability of a cancer tumor to communicate.
4. Delivery of a sequence of bioelectric signals to stop uncontrolled cell division.
5. Delivery of a sequence of bioelectric signals to starve a cancer tumor of blood supply.
6. Delivery of a sequence of bioelectric signals to change the surface protein expressions of a cancer tumor to that the body attacks it - immunotherapy.
7. Reading real time and adjusting real time bioelectric signals to manage inflammation.
8. After cancer tumor has been eradicated from organ a sequence of bioelectric signals to regenerate that organ back to full health and function which includes stem cell homing, controlled proliferation, differentiation and blood vessel sprouting, growth and maturation expression proteins.
"We are delighted to expand the intellectual property around our CancerCell bioelectric therapy designed for destroying cancer tumors and regenerating organs. We have hope that bioelectric cancer therapies can be more effective and less toxic than traditional chemo and radiation therapy protocols. We believe we are the only bioelectric therapy that delivers multiple modalities of treatment to fight the nemesis of cancer tumor growth. We are the only combination therapy known to address eradication of the cancer but also regeneration of the organ following cancer treatment." stated Howard J. Leonhardt, lead inventor and Executive Chairman & CEO of CancerCell and Leonhardt's Launchpads.
"Our team at the Pacific NeuroSciences Institute and the John Wayne Cancer Institute is delighted to have the opportunity to be the first site given the opportunity to study via translational research this unique multi-modality bioelectric therapy for cancer treatment and patient recovery. We look forward to sharing study results soon." Stated Dr. Santosh Kesari, Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neuro-oncology and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
CancerCell announced earlier this year an exclusive option to exclusive license with Neuro Code Tech Holdings LLC that covered multiple related patents - - including these issued patent claims...
Claims
1. A method of treating cancer by causing apoptosis, wherein said cancer is one of a known species of malignant cells, comprising:
creating a confounding electrical signal with respect to said cancer, wherein said confounding electrical signal is applicable to said cancer to cause apoptosis in which said confounding electrical signal is selected from a database of confounding electrical signals; and
applying said confounding signal to said cancer to cause said apoptosis.
2. The method according to claim 1, wherein creating said confounding electrical signal with respect to said cancer further comprises:
determining a resident electrical signal found in a specie of said cancer, and
modifying the resident electrical signal to form said confounding electrical signal.
3. A method of treating cancer by causing apoptosis, said method comprising:
modifying a resident electrical signal found in a cancer to form a confounding electrical signal, and
applying the confounding electrical signal to the cancer to cause apoptosis.
4. A system for treating cancer by causing apoptosis, said system comprising
a first probe for determining a resident electrical signal found in a species of cancer,
a computer system comprising: i. a processor for modifying each resident electrical signal to form at least one confounding electrical signal unique to each resident electrical signal, and ii. a data storage for all confounding electrical signals, and
a second probe for applying a selected one of the confounding electrical signals to the cancer.
"In the past 24 months two major studies have been published confirming the safety and efficacy of bioelectric therapies for cancer treatment by other groups. One was focused on the single modality of jamming the communication ability of aggressive brain tumors and the other on one bioelectric signal sequence to change the surface protein expressions of skin cancer tumors. Those results have excited the entire research area but in our view fall short of a full comprehensive solution. Other studies have demonstrated the efficacy of bioelectric signals in curbing inflammation. Our CancerCell therapy is the only one known to date with eight modalities to fight cancer tumor growth and promote organ regeneration and recovery. We look forward to completing well controlled studies to prove this out over time." states Dr. Leslie Miller, Chief Medical Officer, Leonhardt's Launchpads
"The late Eleanor Schuler taught us that the cancer tumor of January is not the cancer tumor of April and in order to be effective in treating cancer the therapy has to change real time with the tumor changes. Our CancerCell bioelectric therapy is the only one we know of that is designed to do just this." stated further Howard J. Leonhardt, Executive Chairman and CEO.
About CancerCell: CancerCell is pioneering the field of bioelectric therapies for cancer detection, treatment and recovery. CancerCell has developed a portfolio of unique solutions for oncologists and other specialists designed to hopefully help them deliver better care to their patients. The team announced earlier this year the exclusive option license for a series of bioelectric read and write bioelectric cancer treatment patents from inventor Eleanor Schuler and Neuro Code Tech Holdings LLC - https://patents.justia.com/inventor/eleanor-schuler ; CancerCell is incubating in the Leonhardt's Launchpads accelerators in California and Utah. See web site with VIDEO >
About Leonhardt's Launchpads: Founded by Leonhardt Ventures in 2008 Leonhardt's Launchpads focuses on launching startups focused on Regenerative Medtech and Regenerative Economy innovations. 30 startups currently are within the Leonhardt's Launchpads accelerators at four locations in Santa Monica, Playa Vista and Petaluma in California and Salt Lake City, Utah. Leonhardt's Launchpads' majority of startups are all based on Leonhardt Ventures' patented technology platform of bioelectric stimulator and when needed also a micro infusion pump re-filled daily or weekly with a fifteen component mixed stem cell + growth factors organ regeneration composition. Leonhardt's Launchpads accelerators are operated by Cal-X Stars Business Accelerator, Inc. a California C corporation www.calxstars.com majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). Leonhardt's Launchpads Utah, Inc. is a stand alone C corporation in Salt Lake City, Utah The business model of Leonhardt's Launchpads is to advance startups through to first-in-man clinical data and then seek out a strategic specific organ focused partner.
About Leonhardt Ventures: Founded in 1982 by inventor Howard J. Leonhardt -has led the development of a number of leading organ regeneration and recovery products including the world's leading stent graft system for aortic aneurysm repair. Over 500,000 patients to date have been treated with Leonhardt inventions. See www.leonhardtventures.com for more information including links to web sites of all our startups. Registered as Leonhardt Vineyards LLC DBA Leonhardt Ventures since 2005. See web site Click here for Leonhardt's Ventures 2017 Annual Report >
Cautionary Statement: Leonhardt's Launchpads and Leonhardt Ventures specialize in early stage development of organ regeneration and recovery technologies with a very small staff and very small budget compared to competitors in the sector. The technologies are brand new and are unproven for safety and efficacy. By nature of this specialization the investment risk is very high and is not meant for 'nest egg savings and is reserved only for sophisticated accredited investors with experience in these type of investments. Some statements may be forward looking and information may change. Information on linked web sites may be outdated and is prone to errors due to the small staff and budget to maintain their accuracy and updates. All of our patents are subject to upkeep with maintenance fees. All of our agreements with third parties are subject to conditions that must be met to keep them active and valid. If you have any questions requiring clarification of any information or updated information please contact us at the below email addresses or phone voice mail.
Forward-Looking Statement Disclaimer:
Various statements in this release, including, but not limited to statements relating to monetizing its intellectual property, expanding its distribution network, and growing commercial interest internationally constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Leonhardt's Launchpads by Cal-X Stars Business Accelerator, Inc. most recently filed Annual Report and Private Placement Memorandum under 506D Part C In addition, any forward-looking statements represent CancerCell and Leonhardt's Launchpads's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Leonhardt's Launchpads by Cal-X Stars Business Accelerator, Inc, Leonhardt Ventures and CancerCell, do not assume any obligation to update any forward-looking statements unless required by law.
CancerCell Contacts:
Brian Hardy, Director of Marketing, This email address is being protected from spambots. You need JavaScript enabled to view it.
Asli Gozoren, Director of Investor Relations, This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Leslie Miller, Chief Medical Officer, This email address is being protected from spambots. You need JavaScript enabled to view it.
Alex Richardson, VP Engineering and Product Development, This email address is being protected from spambots. You need JavaScript enabled to view it.
Howard J. Leonhardt, Executive Chairman & CEO, This email address is being protected from spambots. You need JavaScript enabled to view it.
Central Google Voice Mail for All Locations: (424) 291-2133
SOURCE: Leonhardt's Launchpads by Cal-X Stars Business Accelerator, Inc. and Leonhardt's Launchpads Utah, Inc.
Leonhardt's Launchpads by Cal-X Stars Business Accelerator, Inc, 520 Broadway, Suite 201, Santa Monica, CA 90401 - www.leonhardtventures.com + www.calxstars.com ;
Leonhardt's Launchpads Playa Vista, 12760 Millennium Dr., Unit 213, Playa Vista, CA 90094 & WeWork Playa Vista, 12655 W. Jefferson Blvd., Playa Vista, C 90066
Leonhardt's Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ BioInnovations Gateway, 2500 S State St. #224, Salt Lake City, UT 84115
MENAFN1910201700703077ID1095966688
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.